Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma

被引:10
|
作者
Abulafia, O
Kleinhaus, K
Levi, G
Lee, YC
Sherer, DM
机构
[1] SUNY Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Brooklyn, NY 11203 USA
[2] SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA
[3] Maimonides Hosp, Brooklyn, NY 11219 USA
[4] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
angiogenesis; uterine leiomyoma; gonadotropin-releasing hormone agonist therapy;
D O I
10.1159/000052953
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the effect of gonadotropin-releasing hormone (GnRH)agonist treatment upon angiogenesis in uterine leiomyomata. Methods: Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant. Results: Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 <plus/minus> 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7). Conclusion: Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [1] The effect of extended gonadotropin-releasing hormone agonist administration on uterine leiomyoma histopathology
    Mukherjee, T
    Abadi, M
    Copperman, AB
    Lapinski, R
    Tsai, T
    Jones, J
    Levgur, M
    JOURNAL OF GYNECOLOGIC SURGERY, 1996, 12 (04) : 251 - 255
  • [2] Gonadotropin-releasing hormone antagonists in the treatment of uterine leiomyoma
    Felberbaum, Ricardo E.
    Kuepker, Wolfgang
    Balogh, Balint
    Diedrich, Klaus
    GYNAKOLOGE, 2020, 53 (08): : 529 - 536
  • [3] Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma
    Higashijima, T
    Kataoka, A
    Nishida, T
    Yakushiji, M
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996, 68 (1-2): : 169 - 173
  • [4] TREATMENT OF UTERINE FIBROIDS WITH AGONIST ANALOGS OF GONADOTROPIN-RELEASING HORMONE
    KESSEL, B
    LIU, J
    MORTOLA, J
    BERGA, S
    YEN, SSC
    FERTILITY AND STERILITY, 1988, 49 (03) : 538 - 541
  • [5] Effect of gonadotropin-releasing hormone agonist on a uterine arteriovenous malformation
    Morikawa, Mamoru
    Yamada, Takashi
    Yamada, Hideto
    Minakami, Hisanori
    OBSTETRICS AND GYNECOLOGY, 2006, 108 (03): : 751 - 753
  • [6] Treatment of Urinary Retention Caused by Uterine Leiomyoma With a Gonadotropin-Releasing Hormone Agonist: Case Report and Review
    Chu, Christine M.
    Dabney, Lisa
    Hardart, Anne
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2013, 19 (01): : 52 - 55
  • [7] Spontaneous expulsion of a uterine submucosal leiomyoma after administration of a gonadotropin-releasing hormone agonist
    Yu, KJ
    Lai, CR
    Sheu, MH
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 96 (02): : 223 - 225
  • [8] TREATMENT OF UTERINE FIBROIDS WITH IMPLANTS OF GONADOTROPIN-RELEASING HORMONE AGONIST - ASSESSMENT BY HYSTEROGRAPHY
    DONNEZ, J
    SANDOW, J
    SCHRURS, B
    CLERCKX, F
    GILLEROT, S
    FERTILITY AND STERILITY, 1989, 51 (06) : 947 - 950
  • [9] Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (Leuprolide acetate)
    Mizutani, T
    Sugihara, A
    Nakamuro, K
    Terada, N
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04): : 1253 - 1255
  • [10] Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma
    Huang, SC
    Tang, MJ
    Cheng, YM
    Hsu, KF
    Ho, CL
    Chou, CY
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10): : 5009 - 5016